Skip to main content
TipRanks
Go Ultimate75% OFF

Healthequity (HQY) AI Stock Analysis

908 Followers
HQY

Healthequity

(NASDAQ:HQY)

Select Model
Rating:73Outperform
Price Target:$109.00▲(11.93% Upside)
Action:reiterated
Date:09/30/26

The score is supported primarily by strong financial performance (profitability turnaround, expanding margins, and robust free cash flow) and a constructive earnings update with raised FY2027 guidance and continued buybacks. Offsetting these strengths, technicals are notably weak with the stock in a downtrend despite oversold readings, and valuation remains somewhat premium (P/E ~31) without dividend support.

Positive Factors
HSA account and asset growthExpanding HSA accounts and assets strengthen HealthEquity’s recurring administration-fee base while increasing custodial, investment-related, and payment revenue opportunities. The combination of record enrollment and strong new-sales growth supports durable scale and deeper distribution across the benefits ecosystem.
Negative Factors
Competitive pressure on service feesService-fee pressure can weaken revenue growth and reduce the benefit of operating scale if client savings are shared more aggressively. Because administration fees are a core revenue stream, continued competition could constrain margin expansion and require ongoing efficiency gains to preserve profitability.

Healthequity (HQY) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%HQY-6.04%SPY+9.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$8.05B
Dividend Yield
―
Average Volume (3M)
884.44K
Price to Earnings (P/E)
34.8
Beta (1Y)
0.73
Revenue Growth
7.33%
EPS Growth
65.97%
Country
US
Employees
2,814
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

Healthequity Business Overview & Revenue Model

Company Description

Headquartered in Draper, Utah, and established in 2002, HealthEquity, Inc. furnishes technology-powered service platforms to both individual consumers and employers across the United States. The company provides cloud-based solutions designed to assi...

How the Company Makes Money

HealthEquity primarily makes money through fees for administering and servicing benefit accounts and through income earned on the assets held in those accounts. 1) Service fees (benefits account administration) - HealthEquity charges administration a...

Healthequity Earnings Call Summary

Earnings Call Date:Aug 27, 2026(Q2-2027)|% Change Since:4.27%|Next Earnings Date:Dec 01, 2026
Earnings Call SentimentPositive

The call conveyed strong operational and financial momentum: accelerated revenue growth, record gross profit and adjusted EBITDA margin expansion, raised fiscal 2027 guidance, robust HSA account and asset growth, meaningful digital and AI-driven efficiency gains, and healthy cash generation enabling share repurchases. Key risks and near-term constraints include marketplace revenue still being immaterial, competitive price pressure on service fees, hedging that limits yield upside, modest total account growth outside HSAs, and a small current share of investing HSA members. Overall, the positive execution, raised guidance, and margin durability materially outweigh the noted challenges.

Positive Updates

Accelerating Revenue Growth
Total revenue growth accelerated to 8% year-over-year in Q2; first-half revenue $705.4M, up 7% year-over-year. Company raised fiscal 2027 revenue guidance to $1.411B–$1.421B.

Negative Updates

Marketplace Revenue Still Immature
Although showing encouraging early engagement (14,000+ active members), management noted marketplace revenue is currently immaterial to overall financial results and must scale significantly before contributing meaningfully to revenue and profit.

Company Guidance

HealthEquity raised its fiscal 2027 outlook, now expecting revenue of $1.411–1.421 billion, GAAP net income of $242–248 million (or $2.88–$2.96 per share), non‑GAAP net income of $392–398 million (or $4.66–$4.73 per share on an estimated 84 million shares), and adjusted EBITDA of $628–636 million; management assumes a GAAP and non‑GAAP tax rate of ~25%. They expect average HSA cash yield of 3.85–3.90% in FY27 and noted $2.3 billion of HSA cash repricing remaining in FY27, $460 million of forward Treasury contracts matured in Q2, $3.0 billion of outstanding forward contracts effectively locking a ~3.9% five‑year Treasury rate (net of costs) across FY27–29, and small forward hedges placed post‑quarter for enhanced‑rate repricings over the next 12–18 months. The company closed the quarter with $256 million of cash, generated $136 million of operating cash flow, had ~$931 million of debt outstanding (net of issuance costs), repurchased about $108 million of shares in Q2 at an average price below $90 and has roughly $948 million remaining under its $1.6 billion repurchase authorization; the guidance reflects continued funding of growth initiatives, planned share repurchases, potential revolver paydowns, and preserved capacity for opportunistic M&A.

Healthequity Financial Statement Overview

Summary

Strong fundamentals driven by a clear shift to durable profitability, meaningful margin expansion (TTM net margin ~17% and gross margin ~73%), and excellent cash generation (TTM FCF ~$472M with strong cash-to-earnings coverage). Main risks are inconsistency in reported debt levels between FY2026 annual vs TTM and some near-term variability in margins/FCF growth that should be monitored.

Income Statement

86Very Positive

Balance Sheet

72Positive

Cash Flow

84Very Positive
Financial statement breakdown
BreakdownTTMJan 2026Jan 2025Jan 2024Jan 2023Jan 2022
Income Statement
Total Revenue1.36B1.31B1.20B999.59M861.75M756.56M
Gross Profit1.02B913.12M692.58M529.87M395.50M340.92M
EBITDA495.07M489.22M337.54M282.42M171.53M102.97M
Net Income236.49M215.20M96.70M55.71M-26.14M-44.29M
Balance Sheet
Total Assets3.27B3.38B3.45B3.16B3.09B3.11B
Cash, Cash Equivalents and Short-Term Investments256.00M318.93M295.95M403.98M254.27M225.41M
Total Debt971.02M1.00B1.11B933.14M994.49M1.01B
Total Liabilities1.28B1.27B1.33B1.13B1.19B1.25B
Stockholders Equity1.99B2.11B2.11B2.04B1.90B1.85B
Cash Flow
Free Cash Flow471.67M455.13M337.77M196.75M31.52M3.91M
Operating Cash Flow490.18M457.09M339.86M242.83M150.65M141.00M
Investing Cash Flow-59.64M-47.14M-505.45M-46.07M-119.13M-639.25M
Financing Cash Flow-479.00M-386.98M57.57M-47.04M-2.67M394.86M

Healthequity Technical Analysis

Technical Analysis SentimentNeutral
Last Price97.38

Price Trends

50DMA96.57Positive
100DMA98.04Negative
200DMA90.29Positive

Market Momentum

MACD0.91Positive
RSI43.34Neutral
STOCH11.34Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HQY, the sentiment is Neutral. The current price of 97.38 is below the 20-day moving average (MA) of 102.58, above the 50-day MA of 96.57, and above the 200-day MA of 90.29, indicating a neutral trend. The MACD of 0.91 indicates Positive momentum. The RSI at 43.34 is Neutral, neither overbought nor oversold. The STOCH value of 11.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HQY.

Healthequity Risk Analysis

Healthequity disclosed 43 risk factors in its most recent earnings report. Healthequity reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Achieving our business strategy depends in large part on the success of our upcoming CEO transition.Q3, 2024
2.Failure to adequately manage the liquidity of the custodial assets held by our Depository Partners and insurance company partners could materially and adversely affect our business, financial condition, and results of operations.Q4, 2023
3.A decline in the value of invested HSA Assets would adversely affect our results of operations.Q4, 2023

Healthequity Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HQY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HNGEHNGE81Outperform$8.79B51.9750.47%―49.86%―
WAYWAY76Outperform$5.21B38.703.41%―21.43%9.80%
HQYHQY73Outperform$8.05B34.7811.43%―7.33%65.97%
OMDAOMDA69Neutral$775.47M52.545.67%―43.34%―
GDRXGDRX64Neutral$1.03B57.412.61%―-1.83%-48.77%
TDOCTDOC56Neutral$1.42B-9.06-11.63%―-2.38%32.73%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%HQYTDOCGDRXWAYHNGEOMDADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HQY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HQYHealthequity Inc97.38-4.53-4.45%
TDOCTeladoc Inc.7.790.8311.93%
GDRXGoodrx Holdings, Inc.3.020.3111.44%
WAYWaystar Holding Corp.27.09-8.65-24.20%
HNGEHinge Health, Inc. Class A108.1062.11135.05%
OMDAOmada Health, Inc.12.50-6.10-32.80%

Healthequity Corporate Events

Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance

HealthEquity Announces Chief Commercial Officer Leadership Change

Neutral
Oct 9, 2026

HealthEquity, Inc. terminated the employment of Chief Commercial Officer Michael Fiore without cause, effective October 5, 2026, and plans to redistribute the CCO’s responsibilities among other members of its management team. Under the terms of his e...

Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance

HealthEquity adds Moody’s CFO Heuland to board

Positive
Sep 30, 2026

On September 24, 2026, HealthEquity appointed Moody’s Corporation Chief Financial Officer Noémie Heuland to its board of directors, expanding the board from ten to eleven members, nine of whom are independent. Heuland will serve on the Audit and Risk...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 30, 2026